B Group, Inc. Cellectis S.A. Transaction History
B Group, Inc.
- $117 Billion
- Q1 2025
A detailed history of B Group, Inc. transactions in Cellectis S.A. stock. As of the latest transaction made, B Group, Inc. holds 3,256,501 shares of CLLS stock, worth $4.88 Million. This represents 3.46% of its overall portfolio holdings.
Number of Shares
3,256,501
Previous 3,081,501
5.68%
Holding current value
$4.88 Million
Previous $5.55 Billion
27.2%
% of portfolio
3.46%
Previous 3.39%
Shares
2 transactions
Others Institutions Holding CLLS
# of Institutions
29Shares Held
11.7MCall Options Held
0Put Options Held
0-
Long Focus Capital Management, LLC San Juan, PR4.72MShares$7.08 Million0.2% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.16 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL1.44MShares$2.16 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$340,3120.0% of portfolio
-
Baillie Gifford & CO139KShares$208,5700.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $68.3M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...